Who
Yuan Xu
Director
Company insider
Files Form 4 as: Director, Fate Therapeutics; Director, Xilio Therapeutics; Director, Akero Therapeutics.
In numbers
- Trades disclosed
- 31
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $24K
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 22 Apr 2021
- Last trade
- 12 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jun 2026filed 15 Jun 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —87,900 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —87,900 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —26,000 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —13,000 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —26,000 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeutics | SEC FORM 4 Code D | —9,398 | filing |
| 11 Jun 2025filed 12 Jun 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | Akero Therapeutics | SEC FORM 4 Code A | —9,398 at $0.00 | filing |
| 29 May 2025filed 30 May 2025 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 6 Aug 2024filed 7 Aug 2024 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,678633 at $4.23 | filing |
| 14 Jun 2024filed 17 Jun 2024 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 8 Jun 2024filed 11 Jun 2024 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code A | —26,000 at $0.00 | filing |
| 7 Jun 2024filed 11 Jun 2024 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 4 Aug 2023filed 7 Aug 2023 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,345632 at $3.71 | filing |
| 23 Jun 2023filed 27 Jun 2023 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 14 Jun 2023filed 15 Jun 2023 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $19K3,460 at $5.58 | filing |
News
Head to Head Survey: Applied Therapeutics (NASDAQ:APLT) vs. Fate Therapeutics (NASDAQ:FATE)FATE · themarketsdaily.com · 25 Oct 2026Analyzing Fate Therapeutics (NASDAQ:FATE) & Applied Therapeutics (NASDAQ:APLT)FATE · dailypolitical.com · 19 Oct 2026Fate Therapeutics Taps Jamie Harrell To Guide Commercial Strategy For FT819 And FT839FATE · rttnews.com · 12 Oct 2026
0 headlines in the last 90 days name Yuan Xu; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.